Biogen plotting next steps in lupus after latest readout

As Biogen seeks to build its immunology franchise, it became the latest company to post encouraging data in lupus, with BIIB059 meeting the primary endpoints in a Phase II trial to treat both cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE).

Biogen Inc. (NASDAQ:BIIB) said Tuesday that

Read the full 476 word article

User Sign In